Tri Chemical Laboratories (4369) Q1 2026 earnings summary

Executive summary

• Net sales for the three months ended April 30, 2025, rose 100.6% year-over-year to ¥6,569 million, with operating profit up 157.6% to ¥1,712 million and profit attributable to owners of parent up 48.7% to ¥1,207 million.

• Comprehensive income decreased 4.0% year-over-year to ¥867 million, reflecting a decline in other comprehensive income despite higher net profit.

Financial highlights

• Gross profit increased to ¥2,485 million from ¥1,252 million year-over-year, while operating profit more than doubled.

• Basic earnings per share rose to ¥37.16 from ¥25.00 year-over-year.

• Total assets increased to ¥38,804 million as of April 30, 2025, up from ¥36,944 million at the previous fiscal year-end.

• Net assets slightly decreased to ¥31,317 million, with a capital adequacy ratio of 80.7%.

Outlook and guidance

• Full-year net sales forecasted at ¥26,000 million, up 37.5% year-over-year, with profit attributable to owners of parent expected to reach ¥5,000 million, up 0.8%.

• Basic earnings per share for the full year projected at ¥153.86.